Literature DB >> 3965046

Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes.

G M Brittenham, A N Schechter, C T Noguchi.   

Abstract

We examined the extent to which the intracellular polymerization of sickle hemoglobin (HbS) can account for the severity of anemia and of vaso-occlusive manifestations in the various sickling syndromes. Polymer formation in sickle cell disease depends principally on the intraerythrocytic hemoglobin composition and concentration. In our studies, the polymer fraction in sickle red cells was determined from reported mean values for hemoglobin composition and mean corpuscular hemoglobin concentration (MCHC) in 12 groups of patients with sickle hemoglobinopathies (homozygotes for HbS, with and without coexistent alpha-thalassemia or various forms of the hereditary persistence of fetal hemoglobin [HPFH], beta+-, beta 0-, and delta beta-thalassemia, and heterozygotes for HbS with HbA). The calculated HbS polymer fractions at full deoxygenation and at physiologic oxygen saturation values were closely correlated with mean blood hemoglobin concentrations. In addition, polymer fraction correlated with the ranking of the sickling syndromes by vaso-occlusive severity. We find that polymer fraction accounts for about 80% of the variability in hemolytic and clinical severity. The method of analysis presented here provides a quantitative and systematic means of assessing the role of polymer formation in the pathophysiologic manifestations of the sickling syndromes. Our results support the hypothesis that the intracellular polymerization of HbS is the primary determinant of the severity of both anemia and clinical symptomatology in the sickle hemoglobinopathies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965046

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  Correction of sickle cell disease by homologous recombination in embryonic stem cells.

Authors:  Li-Chen Wu; Chiao-Wang Sun; Thomas M Ryan; Kevin M Pawlik; Jinxiang Ren; Tim M Townes
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

2.  Retinal vessel autoregulation in sickle cell patients.

Authors:  J C van Meurs; J Schwoerer; B Schwartz; P G Mulder; H J Meiselmann; C S Johnson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

3.  High-throughput assessment of hemoglobin polymer in single red blood cells from sickle cell patients under controlled oxygen tension.

Authors:  Giuseppe Di Caprio; Ethan Schonbrun; Bronner P Gonçalves; Jose M Valdez; David K Wood; John M Higgins
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-25       Impact factor: 11.205

4.  Electrical impedance microflow cytometry with oxygen control for detection of sickle cells.

Authors:  Jia Liu; Yuhao Qiang; Ofelia Alvarez; E Du
Journal:  Sens Actuators B Chem       Date:  2017-08-24       Impact factor: 7.460

5.  Metastable mesoscopic clusters in solutions of sickle-cell hemoglobin.

Authors:  Weichun Pan; Oleg Galkin; Luis Filobelo; Ronald L Nagel; Peter G Vekilov
Journal:  Biophys J       Date:  2006-10-13       Impact factor: 4.033

6.  LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo.

Authors:  Y Terry Lee; Jaira F de Vasconcellos; Joan Yuan; Colleen Byrnes; Seung-Jae Noh; Emily R Meier; Ki Soon Kim; Antoinette Rabel; Megha Kaushal; Stefan A Muljo; Jeffery L Miller
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

7.  Imaging flow cytometry for automated detection of hypoxia-induced erythrocyte shape change in sickle cell disease.

Authors:  Eduard J van Beers; Leigh Samsel; Laurel Mendelsohn; Rehan Saiyed; Kleber Y Fertrin; Christine A Brantner; Mathew P Daniels; James Nichols; J Philip McCoy; Gregory J Kato
Journal:  Am J Hematol       Date:  2014-04-12       Impact factor: 10.047

Review 8.  Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies.

Authors:  S P Perrine; D V Faller
Journal:  Experientia       Date:  1993-02-15

9.  Combined hydroxyurea and ETA receptor blockade reduces renal injury in the humanized sickle cell mouse.

Authors:  Crystal Taylor; Malgorzata Kasztan; Binli Tao; Jennifer S Pollock; David M Pollock
Journal:  Acta Physiol (Oxf)       Date:  2018-09-20       Impact factor: 6.311

10.  Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.

Authors:  Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik
Journal:  Blood       Date:  2015-08-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.